Aflibercept 2 mg biosimilars-will they lead the Anti-VEGF biosimilar world globally.

Sharma A, Woo SJ, Lee CS, Kumar N, Parachuri N, Bandello F, Loewenstein A, Kuppermann BD

DOI: 10.1038/s41433-025-03732-2
Published: 2025 Apr
Container: Eye (London, England)
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41433-025-03732-2,
  title = {Aflibercept 2 mg biosimilars-will they lead the Anti-VEGF biosimilar world globally.},
  author = {Sharma A and Woo SJ and Lee CS and Kumar N and Parachuri N and Bandello F and Loewenstein A and Kuppermann BD},
  year = {2025},
  journal = {Eye (London, England)},
  doi = {10.1038/s41433-025-03732-2},
  url = {https://doi.org/10.1038/s41433-025-03732-2}
}

RIS

TY  - JOUR
TI  - Aflibercept 2 mg biosimilars-will they lead the Anti-VEGF biosimilar world globally.
AU  - Sharma A
AU  - Woo SJ
AU  - Lee CS
AU  - Kumar N
AU  - Parachuri N
AU  - Bandello F
AU  - Loewenstein A
AU  - Kuppermann BD
PY  - 2025
JO  - Eye (London, England)
DO  - 10.1038/s41433-025-03732-2
UR  - https://doi.org/10.1038/s41433-025-03732-2
ER  -

APA

A, S., SJ, W., CS, L., N, K., N, P., F, B., A, L., & BD, K. (2025). Aflibercept 2 mg biosimilars-will they lead the Anti-VEGF biosimilar world globally.. Eye (London, England). https://doi.org/10.1038/s41433-025-03732-2

Source records

pubmed · retrieved 2026-09-26T15:42:43.244Z